Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma

Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation: A Randomized, Double-Blind, Controlled Trial (RCT)

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01584726

Enrollment

400

Registered

2012-04-25

Start date

2012-12-31

Completion date

2015-12-31

Last updated

2014-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

magnesium, nebulization, asthma, sulfate, children, pediatric

Brief summary

The purpose of this study is to investigate the use of magnesium sulfate nebulization in patient with moderate to severe asthma exacerbation in pediatric emergency.

Detailed description

the use of magnesium sulfate nebulization in patient with moderate to severe asthma exacerbation in pediatric emergency follow asthma severity score and length of stay

Interventions

DRUGMagnesium Sulfate

single dose of magnesium sulfate nebulization

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

2 Years to 14 Years

Healthy volunteers

Inclusion criteria

* Pediatric asthma patients with moderate to severe exacerbation

Exclusion criteria

* Known allergy to magnesium sulfate * History of neuromuscular disease, cardiac disease, renal disease, or underlying chronic lung disease * Use of oral steroid medication within 72 hours of presentation * Radiographic evidence of pneumonia at presentation * Administration of intravenous magnesium sulfate prior to study enrollment

Design outcomes

Primary

Measure	Time frame
Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma significantly reduce the time to clinical readiness for discharge?	36 months

Secondary

Measure	Time frame	Description
• Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma decrease admission and readmission rate, compared to placebo	36 months	* Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma decrease PICU admission rate, compared to placebo? * Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma improve change in asthma severity score at 4, 8, 12 hours, compared to placebo? * Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma decrease return rate to emergency services, compared to placebo? * Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma decrease rate of infirmray admission in follow up, compared to placebo?

Countries

Qatar

Contacts

Primary ContactDr. Khalid Al Ansari, MD,FRCP,FAAP

dkmaa@hotmail.com97444396001

Backup ContactDr. Wessam Mouharam, MD

wessam_mouharam@yahoo.com97444396022

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026